Anti-TB evaluation of novel 2,3-dihydroquinazolin-4(1H)-ones and in silico studies of the active compounds

In vitro anti-tubercular activity of a series 15 novel 2,3-dihydroquinazolin-4(1H)-one analogues were evaluated against Mycobacterium tuberculosis H37Ra (ATCC 25177 strain). Among the series, seven compounds showed moderate to good anti-TB with minimum inhibitory concentration (MIC) values ranging from 25.0–12.5 ?g/mL. Further, in silico experiments carried out identify probable ligand-protein interaction. Molecular docking target into active site enzymes 1DQY Antigen 85C Tuberculosis and 2NSD Enoyl Acyl Carrier Protein Reductase reveals notable information on possible binding interactions.